Four triagonists have been developed (MAR423, retatrutide, SAR441225, and HM15211) and are currently undergoing preclinical trials to verify their potency and biological safety
Start your intake How Tirzepatide Works and Thyroid Concerns Tirzepatide activates two hormone receptorsGLP-1 and GIPthat regulate appetite, blood sugar, and how quickly food moves through your stomach
Most people seem to find the self-injection process easy, and quickly get used to administering the medication themselves
Shulha, H
Neth Heart J
NICE Technology Appraisal guidance (TA875 for semaglutide/Wegovy and TA664 for liraglutide/Saxenda) recommends these medications for weight management in adults with: A body mass index (BMI) of at least 35 kg/m and At least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or non-alcoholic fatty liver disease) For liraglutide (Saxenda), NICE TA664 specifies additional criteria including prediabetes (HbA1c 42-47 mmol/mol or fasting plasma glucose 5.5-6.9 mmol/L) or high risk of cardiovascular disease